A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Trial Profile

A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Planning
Phase of Trial: Phase II

Latest Information Update: 31 May 2018

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Therapix Biosciences
  • Most Recent Events

    • 31 May 2018 According to a Therapix Biosciences media release, the company anticipates to enrol first patient by the end of the third quarter. Top line results are expected in the first half of 2019.
    • 09 Apr 2018 According to Therapix Biosciences Ltd. media release, based on the data from a Phase IIa trial (see profile 700273303) the company is planning to this trial.
    • 07 Feb 2018 According to a Therapix Biosciences media release, company is intended to submit the IND for THX-110 via the 505(b)(2) pathway to initate trial in USA and expects to initiate the trial in second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top